Akero Therapeutics to Present at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference
October 17 2023 - 4:05PM
Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company
developing transformational treatments for patients with serious
metabolic disease marked by high unmet medical need, today
announced management will present virtually at the H.C. Wainwright
7th Annual NASH Conference on Tuesday, October 24, 2023, at 12:00
p.m. E.T.
A live webcast of the fireside chat will be available through
the investor relations section of the Company's website at
www.akerotx.com. Following the live webcast, an archived replay
will be available on the Company's website.
About Akero TherapeuticsAkero Therapeutics is a
clinical-stage company developing transformational treatments for
patients with serious metabolic diseases marked by high unmet
medical need, including NASH, a disease without any approved
therapies. Akero's lead product candidate, EFX, is a differentiated
Fc-FGF21 fusion protein that has been engineered to mimic the
balanced biological activity profile of native FGF21, an endogenous
hormone that alleviates cellular stress and regulates metabolism
throughout the body. EFX is designed to offer convenient
once-weekly subcutaneous dosing. EFX is currently being evaluated
in two Phase 2b clinical trials: the HARMONY study in patients with
pre-cirrhotic NASH (F2-F3 fibrosis), and the SYMMETRY study in
patients with cirrhotic NASH (F4 fibrosis, compensated). Akero is
headquartered in South San Francisco. Visit us
at akerotx.com and follow us
on LinkedIn and Twitter for more
information.
Investor Contact: Austin
Murtagh212.698.8696IR@akerotx.com
Media Contact: Sarah
O’Connell732.456.0092soconnell@vergescientific.com
Akero Therapeutics (NASDAQ:AKRO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Akero Therapeutics (NASDAQ:AKRO)
Historical Stock Chart
From Jul 2023 to Jul 2024